Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | RBP4 | P02753 | 3/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3825636 | 0.88 | HRH4 (0.48) | HRH3HRH4NR1H2NR1H3PIM1 | |
| SCHEMBL3825643 | 0.88 | HRH4 (0.48) | HRH3HRH4NR1H2NR1H3PIM1 | |
| SCHEMBL3820827 | 0.85 | CYP1A2 (0.47) | HRH3HRH4NR1H2NR1H3ADRB2 | |
| SCHEMBL17537344 | 0.79 | ADRB2 (0.48) | NR1H2NR1H3ADRB2MAPTCYP1A2 | |
| SCHEMBL23779477 | 0.78 | ADRB2 (0.47) | NR1H2NR1H3ADRB2MAPTCYP1A2 | |
| SCHEMBL21181781 | 0.78 | ADRB2 (0.47) | NR1H2NR1H3ADRB2MAPTCYP1A2 | |
| SCHEMBL17537350 | 0.76 | MBOAT4 (0.41) | NR1H2NR1H3ADRB2RBP4MAPT | |
| SCHEMBL21181747 | 0.76 | MAP4K4 (0.48) | NR1H2NR1H3ADRB2PIM1PIM2 | |
| SCHEMBL12946112 | 0.75 | CNR2 (0.50) | ADRB2MAPTCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL17537345 | 0.75 | NR3C2 (0.47) | NR1H2NR1H3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2006-12-07 | — | — | US | claimed |
| EP-1601665-A2 | UREA DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-07 | — | — | EP | claimed |
| WO-2004078744-A2 | UREA DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | WO | claimed |
| US-7514562-B2 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1601665-A2 | UREA DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078744-A2 | UREA DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | TRPV1, UTS2R, OPRL1 | HRH3 208/4885HRH4 66/4885NR1H2 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.